We suggest that interruption of anticoagulant therapy in a patient with AF/AFL is not necessary for most procedures with a very low risk of bleeding, including cardiac device implantation (pacemaker or implantable defibrillator) (see Table 1) (Conditional Recommendation, Low Quality Evidence, High Quality Evidence for cardiac device implantation)